New Jersey 2026-2027 Regular Session

New Jersey Senate Bill S2894

Introduced
1/13/26  

Caption

Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

Impact

If enacted, S2894 would significantly impact state regulations surrounding the pharmaceutical industry. The creation of the commission is intended to enhance the growth of active pharmaceutical ingredient manufacturing in New Jersey, facilitating better monitoring and support for this sector. This is particularly relevant as the state navigates the challenges posed by dependence on external sources for pharmaceutical ingredients. The commission would also be responsible for identifying federal funding possibilities which could bolster local manufacturers, thereby promoting both economic growth and public health.

Summary

Senate Bill S2894 proposes the establishment of the New Jersey Active Pharmaceutical Ingredient Regulatory Commission. This commission aims to oversee and regulate the manufacturing of active pharmaceutical ingredients within the state and ensure compliance with federal laws. Comprised of 17 members, including public members appointed by the Governor and individuals from governmental and educational institutions, the commission emphasizes diversity, seeking to include women and minorities in its composition. The bill reflects a growing recognition of the importance of oversight in pharmaceutical manufacturing, particularly in light of vulnerabilities that have been identified in supply chains, highlighted by recent federal executive orders on this matter.

Contention

Notably, while the bill aims to provide critical oversight and enhance local industry growth, it may face scrutiny over the effectiveness of its governance structure and the potential for bureaucratic delays. Opponents may argue that another layer of regulation could complicate rather than simplify the operational framework for pharmaceutical companies. Concerns could arise about balancing stringent oversight with the need for rapid innovation and responsiveness in a fast-paced industry, underscoring the need for ongoing dialogue among stakeholders as the commission takes shape.

Companion Bills

NJ S1161

Carry Over Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

NJ A1838

Carry Over Establishes New Jersey Active Pharmaceutical Ingredient Regulatory Commission.

Similar Bills

NJ A538

"Pharmaceutical Representative Licensing Act."

AR HB1301

To Amend The Prior Authorization Transparency Act.

CT SB01355

An Act Concerning Prescription Drugs, Devices And Nonlegend Drugs.

KY SB2

AN ACT relating to correctional facilities.

NJ S2990

Regulates provision of pharmaceutical services in long-term care facilities.

NJ A3359

Regulates provision of pharmaceutical services in nursing homes.

FL S0860

Compounded Drugs

MA S895

To promote transparency and prevent price gouging of pharmaceutical drug prices